Application of poly(ethylene glycol)- distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4185-4198

  Wang, Rongrong ^a   Xiao, Renzhong ^a   Zeng, Zhaowu ^a   Xu, Lili ^a   Wang, Junjie ^a  

^a HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Mal PEG DSPE; PEG DSPE; PEG lipid; Targeting delivery

Indexed keywords

AMINO TERMINATED POLY(ETHYLENE GLYCOL)DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ARGININE; ASPARTIC ACID; CARBOXYL TERMINATED POLY(ETHYLENE GLYCOL)DISTEAROYLPHOSPHATIDYLETHANOLAMINE; CD19 ANTIGEN; COPOLYMER; GLYCINE; MALEIMIDE TERMINATED POLY(ETHYLENE GLYCOL)DISTEAROYLPHOSPHATIDYLETHANOLAMINE; NANOPARTICLE; POLY(ETHYLENE GLYCOL)DISTEAROYLPHOSPHATIDYLETHANOLAMINE DERIVATIVE; TRIETHYLAMINE; UNCLASSIFIED DRUG;

AMINATION; AMINO ACID ANALYSIS; CANCER CELL; CARBOXYLATION; CHEMICAL MODIFICATION; CIRCULATION TIME; DRUG DELIVERY SYSTEM; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; LIPOSOMAL DELIVERY; MALEYLATION; MICROEMULSION; POLYMERIZATION; REVIEW; THIN LAYER CHROMATOGRAPHY;

ANIMALS; CELL LINE; DRUG CARRIERS; HUMANS; MICE; NANOSTRUCTURES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS;

EID: 84870365664     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34489     Document Type: Review

References (128)

1. Zhang L, Chan JM, Gu FX, etal. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8): 1696-1702.
2. Dos Santos N, Allen C, Doppen AM, etal. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 2007; 1768(6):1367-1377.
3. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res. 2008;14(24):8161-8168.
4. Sriwongsitanont S, Ueno M. Effect of a PEG lipid (DSPE-PEG2000) and freeze-thawing process on phospholipid vesicle size and lamellarity. Colloid Polym Sci. 2004;282(7):753-760.
5. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
6. Song S, Liu D, Peng J, etal. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(1-2):155-161.
7. Kang H, O'Donoghue MB, Liu H, Tan W. A liposome-based nanostructure for aptamer directed delivery. Chem Commun. 2010; 46(2):249-251.
8. Su JC, Tseng CL, Chang TG, Yu WJ, Wu SK. A synthetic method for peptide-PEG-lipid conjugates: application of octreotide-PEG-DSPE synthesis. Bioorg Med Chem Lett. 2008;18(16):4593-4596.
9. Karathanasis E, Geigerman CM, Parkos CA, Chan L, Bellamkonda RV, Jaye DL. Selective targeting of nanocarriers to neutrophils and monocytes. Ann Biomed Eng. 2009;37(10):1984-1992.
10. Vaidya B, Agrawal G, Vyas SP. Platelets directed liposomes for the delivery of streptokinase: development and characterization. Eur J Pharm Sci. 2011;44(5):589-594.
11. Ishida O, Maruyama K, Tanahashi H, etal. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res. 2001;18(7): 1042-1048.
12. Lopez-Barcons LA, Polo D, Reig F, Fabra A. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes. J Biomed Mater Res A. 2004; 69A(1):155-163.
13. Otsubo T, Maruyama K, Maesaki S, etal. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother. 1998;42(1):40-44.
14. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta. 1995;1234(1):74-80.
15. Zalipsky S, Brandeis E, Newman MS, Woodle MC. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 1994;353(1):71-74.
16. Goren D, Horowitz A, Zalipsky S, Woodle M, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer. 1996;74(11):1749-1756.
17. Koning GA, Morselt HWM, Gorter A, etal. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res. 2003;20(8):1249-1257.
18. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem. 1993;4(4):296-299.
19. Cuong NV, Hsieh MF. Molecular targeting of liposomal nano-particles to lymphatic system. Curr Cancer Drug Targets. 2011;11(2): 147-155.
20. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem. 2007;18(1):101-108.
21. Koning GA, Kamps JAAM, Scherphof GL. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes. Cancer Detect Prev. 2002;26(4):299-307.
22. Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32(12):3265-3274.
23. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 2011;153(2):141-148.
24. Kirpotin D, Park JW, Hong K, etal. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36(1):66-75.
25. Gabizon A, Horowitz AT, Goren D, etal. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. 1999;10(2):289-298.
26. Zhao BJ, Ke XY, Huang Y, etal. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target. 2011;19(5): 382-390.
27. Yamano S, Dai J, Yuvienco C, Khapli S, Moursi AM, Montclare JK. Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolae-mediated endocytosis. J Control Release. 2011;152(2):278-285.
28. Turk MJ, Breur GJ, Widmer WR, etal. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002;46(7):1947-1955.
29. Gabizon A, Tzemach D, Gorin J, etal. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol. 2010;66(1):43-52.
30. Riviere K, Huang Z, Jerger K, Macaraeg N, Szoka FC Jr. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration. J Drug Target. 2011;19(1): 14-24.
31. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-763.
32. Chiu SJ, Marcucci G, Lee RJ. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. Anticancer Res. 2006;26(2A):1049-1056.
33. Doi A, Kawabata S, Iida K, etal. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol. 2008;87(3): 287-294.
34. Yang X, Koh CG, Liu S, etal. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2008;6(1):221-230.
35. Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm. 2010;396(1-2):143-148.
36. Song S, Liu D, Peng J, etal. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J. 2009;23(5):1396-1404.
37. Zhu J, Xue J, Guo Z, Zhang L, Marchant RE. Biomimetic glycoliposomes as nanocarriers for targeting P-selectin on activated platelets. Bioconjug Chem. 2007;18(5):1366-1369.
38. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int J Pharm. 2009;379(2):293-300.
39. Xiong XB, Huang Y, Lu WL, etal. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: In vitro and in vivo. J Pharm Sci. 2005;94(8): 1782-1793.
40. Jiang J, Yang S, Wang J, etal. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm. 2010;76(2):170-178.
41. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm. 2006; 3(5):579-588.
42. Önyüksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009; 365(1-2):157-161.
43. Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived therapeutic antibodies. Curr Pharm Biotechnol. 2008;9(6): 439-446.
44. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118-129.
45. Maynard J, Georgiou G. Antibody engineering. Annu Rev Biomed Eng. 2000;2(1):339-376.
46. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res. 2004;10(7): 2530-2537.
47. O'Donnell R, Martin S, Ma Y, Zamboni W, Tuscano J. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drug. 2010;28(3):260-267.
48. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58(15):3320-3330.
49. Mamot C, Drummond DC, Greiser U, etal. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63(12):3154-3161.
50. Rothdiener M, Müller D, Castro PG, etal. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release. 2010;144(2):251-258.
51. Hayes M, Drummond D, Kirpotin D, etal. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2005;13(7):646-651.
52. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 1997;413(1):177-180.
53. Cheng WWK, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2008; 126(1):50-58.
54. Allen TM, Mumbengegwi DR, Charrois GJR. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res. 2005;11(9):3567-3573.
55. Lapalombella R, Yu B, Triantafillou G, etal. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112(13):5180-5189.
56. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010;16(10):2760-2768.
57. Drummond DC, Marx C, Guo Z, etal. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005;11(9):3392-3401.
58. Nielsen UB, Kirpotin DB, Pickering EM, etal. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002;1591(1-3): 109-118.
59. Hu CMJ, Kaushal S, Cao HST, etal. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm. 2010;7(3):914-920.
60. Maruyama K, Takizawa T, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev. 1997;24(2-3):235-242.
61. Moreira JN, Gaspar R, Allen TM. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta. 2001;1515(2):167-176.
62. Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res. 2002; 19(3):265-269.
63. Bohl Kullberg E, Bergstrand N, Carlsson J, etal. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem. 2002;13(4):737-743.
64. Pastorino F, Brignole C, Marimpietri D, etal. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003;63(1):86-92.
65. Koning GA, Morselt HWM, Gorter A, etal. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharm Res. 2001;18(9):1291-1298.
66. Huang L, Kennel SJ. Binding of immunoglobulin G to phospholipid vesicles by sonication. Biochemistry. 1979;18(9):1702-1707.
67. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93(8):1980-1992.
68. Yan Z, Wang F, Wen Z, etal. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release. 2011;157(1):118-125.
69. Gill K, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG (5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011;79(2):276-284.
70. Xu Z, Zhang Z, Chen Y, Chen L, Lin L, Li Y. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials. 2010;31(5):916-922.
71. Han X, Liu J, Liu M, etal. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm. 2009;372(1-2):125-131.
72. Shmeeda H, Amitay Y, Gorin J, etal. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release. 2010;146(1):76-83.
73. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999; 460(1):129-133.
74. Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett. 2002;7(2): 217-219.
75. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys. 2001;1513(2):207-216.
76. Vader P, Crielaard BJ, van Dommelen SM, van der Meel R, Storm G, Schiffelers RM. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. J Control Release. 2011;160(2):211-216.
77. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113(2):171-199.
78. Bakker-Woudenberg IAJM. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents. 2002;19(4):299-311.
79. Allen C, Dos Santos N, Gallagher R, etal. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly (ethylene glycol). Biosci Rep. 2002;22(2): 225-250.
80. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta. 1989;981(1):27-35.
81. Kim K, Yu M, Zong X, etal. Control of degradation rate and hydrophilicity in electrospun non-woven poly(d, l-lactide) nanofiber scaffolds for biomedical applications. Biomaterials. 2003;24(27):4977-4985.
82. Gref R, Lück M, Quellec P, etal. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313.
83. Bradley AJ, Murad KL, Regan KL, Scott MD. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter. Biochim Biophys Acta. 2002;1561(2):147-158.
84. Zhu A, Lu P, Wu H. Immobilization of poly(-caprolactone)-poly(ethylene oxide)-poly(-caprolactone) triblock copolymer on poly(lactide-co-glycolide) surface and dual biofunctional effects. Appl Surf Sci. 2007;253(6):3247-3253.
85. Papahadjopoulos D, Allen T, Gabizon A, etal. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460-11464.
86. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys. 1991;1066(1): 29-36.
87. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharm. 1999;43(1):1-7.
88. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
89. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-131.
90. Guo J, Gao X, Su L, etal. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010-8020.
91. Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release. 2011;156(2):203-211.
92. Diao YY, Li HY, Fu YH, etal. Doxorubicin-loaded PEG-PCL copolymer micelles enhance cytotoxicity and intracellular accumulation of doxorubicin in adriamycin-resistant tumor cells. Int J Nanomed. 2011;6:1955-1962.
93. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44(10):1123-1134.
94. Hattori Y, Maitani Y. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release. 2004;97(1):173-183.
95. Han X, Liu J, Liu M, etal. 9-nitro-camptothecin-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm. 2009;372(1-2):125-131.
96. Wang J, Maitani Y, Takayama K. Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. J Pharm Sci. 2002;91(4): 1128-1134.
97. Stevens PJ, Lee RJ. A folate receptor-targeted emulsion formulation for paclitaxel. Anticancer Res. 2003;23(6C):4927-4931.
98. Shiokawa T, Hattori Y, Kawano K, etal. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res. 2005;11(5):2018-2025.
99. Junping W, Takayama K, Nagai T, Maitani Y. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int J Pharm. 2003; 251(1-2):13-21.
100. Zhang L, Chan JM, Gu FX, etal. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8): 1696-1702.
101. Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S. Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev. 2011; 63(14-15):1340-1351.
102. Chan JM, Zhang L, Yuet KP, etal. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8): 1627-1634.
103. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther. 2006;317(3):1372-1381.
104. Müller R, Radtke M, Wissing S. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-S155.
105. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
106. Stevens PJ, Sekido M, Lee RJ. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res. 2004;24(1):161-165.
107. Kuo YC, Liang CT. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B Biointerfaces. 2011;85(2):131-137.
108. Hayes M, Drummond D, Hong K, Park J, Marks J, Kirpotin D. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta. 2006;1758(4):429-442.
109. Dass CR, Choong PFM. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release. 2006;113(2):155-163.
110. Kim JK, Choi SH, Kim CO, Park JS, Ahn WS, Kim CK. Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J Pharm Pharmacol. 2003;55(4):453-460.
111. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1): 93-102.
112. Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J. 2007;36(4): 349-362.
113. Stuart DD, Kao GY, Allen TM. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Adv Exp Med Biol. 2000;7(3):466-475.
114. Gura T. After a setback, gene therapy progresses. gingerly. Science. 2001;291(5509):1692-1697.
115. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer. 2003;3(7): 477-488.
116. Thayer AM. Improving peptides. Chem Eng News. 2011;89(22): 13-20.
117. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J. 2006;8(3):466-478.
118. Woodle MC, Storm G, Newman MS, etal. Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm Res. 1992;9(2):260-265.
119. Lim SB, Rubinstein I, Önyüksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm. 2008; 356(1-2):345-350.
120. Lajavardi L, Bochot A, Camelo S, etal. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2007;48(7): 3230-3238.
121. Kibria G, Hatakeyama H, Harashima H. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int J Pharm. 2011;412(1-2):106-114.
122. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials. 2011;32(26):6194-6203.
123. Zhai G, Wu J, Yu B, Guo C, Yang X, Lee RJ. A transferrin receptor-targeted liposomal formulation for docetaxel. J Nanosci Nanotechnol. 2010;10(8):5129-5136.
124. Vladimir PT. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73(2-3):137-172.
125. Xiong XB, Huang Y, Lu WI, etal. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107(2):262-275.
126. Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2006;13(2):328-337.
127. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35-42.
128. Dams E, Laverman P, Oyen WJG, etal. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-1079.